| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
INE-963 targets the blood-stage of Plasmodium parasites, including P. falciparum and P. vivax. The compound demonstrates potent activity against P. falciparum 3D7 with an EC₅₀ of 6 nM. It has a fast-killing profile with parasite clearance in less than 24 hours. The compound is effective against a range of P. falciparum and P. vivax isolates with EC₅₀ values of 0.01-7 nM. INE-963 has a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. The exact molecular target is not specified in the available literature.
|
|---|---|
| ln Vitro |
In vitro, INE-963 demonstrates potent activity against P. falciparum 3D7 with an EC₅₀ of 6 nM. The compound exhibits a fast-killing profile with "artemisinin-like" killing kinetics and parasite clearance in less than 24 hours. INE-963 is effective against P. falciparum and P. vivax isolates with EC₅₀ values ranging from 0.01-7 nM. The compound has a high barrier to resistance, suggesting it may be less prone to the development of resistance compared to other antimalarials. It is used as a research tool for studying antimalarial drug development.
|
| ln Vivo |
In vivo, INE-963 has potential for single-dose cures in uncomplicated malaria. The compound's fast-killing kinetics and potent activity against Plasmodium parasites make it a promising candidate for malaria treatment. Animal studies would be needed to evaluate the compound's efficacy in clearing parasitemia and preventing recrudescence. INE-963 has a high barrier to resistance, which is important for antimalarial drug development. Further in vivo studies are needed to fully characterize its efficacy and safety profile.
|
| Enzyme Assay |
In vitro antimalarial assays for INE-963 involve measuring growth inhibition of P. falciparum in culture. The standard protocol includes culturing P. falciparum 3D7 parasites in human red blood cells with varying concentrations of INE-963 (0.001-1000 nM) for 48-72 hours. Parasite growth is assessed by measuring [³H]-hypoxanthine incorporation or by fluorescence-based methods using SYBR Green I. EC₅₀ values are calculated from dose-response curves. Killing kinetics are assessed by time-kill assays to determine the rate of parasite clearance.
|
| Cell Assay |
Cell-based assays for INE-963 are conducted in P. falciparum cultures. Parasites are cultured in human erythrocytes with RPMI 1640 medium supplemented with Albumax. INE-963 is added at concentrations ranging from 0.001-1000 nM. Parasitemia is assessed by microscopic examination of Giemsa-stained blood smears or by flow cytometry. Growth inhibition is measured by [³H]-hypoxanthine incorporation or SYBR Green I fluorescence. The compound's activity against drug-resistant strains is assessed using P. falciparum lines with known resistance mutations.
|
| Animal Protocol |
In vivo animal experiments for INE-963 would typically use mouse models of malaria (e.g., P. berghei-infected mice or humanized mouse models with P. falciparum). Animals would be administered INE-963 via oral gavage or intravenous injection at doses determined from PK studies. Parasitemia would be monitored by blood smear microscopy or flow cytometry. Survival and cure rates would be assessed. Pharmacokinetic studies would be performed to determine exposure and bioavailability. The compound's potential for single-dose cure would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for INE-963 are not extensively reported. As a small molecule with a molecular weight of 402.51 g/mol, the compound is expected to have favorable oral bioavailability. Storage: typically at -20°C. Purity is typically ≥98%. The compound is a potent and fast-acting antimalarial with EC₅₀ values of 3-6 nM. Further PK studies would be required for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
INE-963 is supplied for research use only and is not intended for human administration. Toxicity data are limited, but the compound is being developed as a potential antimalarial agent. Standard laboratory safety precautions should be followed when handling Plasmodium cultures and the compound. No specific toxicological studies have been published. The compound should be handled with care and stored appropriately.
|
| References | |
| Additional Infomation |
INE-963 (CAS 2640567-43-5) is a research compound supplied for laboratory use only. It is not an approved drug and has no marketing authorization status. The compound is a potent and fast-acting blood-stage antimalarial with an EC₅₀ of 6 nM against P. falciparum 3D7. It has "artemisinin-like" killing kinetics with parasite clearance in <24 hours. Purity is typically ≥98%. The compound has potential for single-dose cures in uncomplicated malaria.
|
| Molecular Formula |
C19H26N6O2S
|
|---|---|
| Molecular Weight |
402.51
|
| Exact Mass |
402.18
|
| Elemental Analysis |
C, 56.70; H, 6.51; N, 20.88; O, 7.95; S, 7.96
|
| CAS # |
2640567-43-5
|
| Related CAS # |
2640567-43-5;INE963 HCl;
|
| PubChem CID |
156274257
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
533
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JYHSRMKXBAPFST-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H26N6O2S/c1-12(2)14-5-4-13(16(22-14)27-3)15-10-21-17-25(15)23-18(28-17)24-8-6-19(26,11-20)7-9-24/h4-5,10,12,26H,6-9,11,20H2,1-3H3
|
| Chemical Name |
4-(aminomethyl)-1-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]piperidin-4-ol
|
| Synonyms |
INE963; INE 963; INE-963;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~248.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4844 mL | 12.4221 mL | 24.8441 mL | |
| 5 mM | 0.4969 mL | 2.4844 mL | 4.9688 mL | |
| 10 mM | 0.2484 mL | 1.2422 mL | 2.4844 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
